Overexpression of TNF-α-converting enzyme in fibroblasts augments dermal fibrosis after inflammation

Laboratory Investigation

Volumn 93, Issue 1, 2013, Pages 72-80

  Fukaya, Shinji ^a   Matsui, Yuki ^b   Tomaru, Utano ^a   Kawakami, Ai ^b   Sogo, Sayuri ^b   Bohgaki, Toshiyuki ^a   Atsumi, Tatsuya ^a   Koike, Takao ^a   Kasahara, Masanori ^a   Ishizu, Akihiro ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

EGFR; fibrosis; inflammation; PMA; TACE

Indexed keywords

COLLAGEN TYPE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FURIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CELL SURFACE; CONTROLLED STUDY; FIBROBLAST; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCAR FORMATION; SKIN FIBROSIS; SURFACE PROPERTY; TRANSGENE;

ADAM PROTEINS; ANIMALS; COLLAGEN TYPE I; FEMALE; FIBROBLASTS; FIBROSIS; FURIN; HISTOCYTOCHEMISTRY; IMMUNE SYSTEM PROCESSES; INFLAMMATION; MICE; MICE, TRANSGENIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; TETRADECANOYLPHORBOL ACETATE;

EID: 84871791476     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.153     Document Type: Article

References (21)

1. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature 1997;385:729-733. (Pubitemid 27098094)
2. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Nature 1997;385:733-736. (Pubitemid 27098095)
3. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990;87:5578-5582.
4. Grams F, Huber R, Kress LF, et al. Activation of snake venom metalloproteinases by a cysteine switch-like mechanism. FEBS Lett 1993;335:76-80. (Pubitemid 23347740)
5. Kang T, Zhao YG, Pei D, et al. Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites. J Biol Chem 2002;277:25583-25591. (Pubitemid 34951875)
6. Endres K, Anders A, Kojro E, et al. Tumor necrosis factor-a converting enzyme is processed by proprotein-convertases to its mature form which is degraded upon phorbol ester stimulation. Eur J Biochem 2003;270:2386-2393. (Pubitemid 36645356)
7. Doggrell SA. TACE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs 2002;11:1003-1006. (Pubitemid 34732718)
8. Shimizu M, Hasegawa N, Nishimura T, et al. Effects of TNF-a-converting enzyme inhibition on acute lung injury induced by endotoxin in the rat. Shock 2009;32:535-540.
9. Terao M, Murota H, Kitaba S, et al. Tumor necrosis factor-a processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Exp Dermatol 2010;19:38-43.
10. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-220. (Pubitemid 24236777)
11. Maltzan K, Tan W, Pruett SB. Investigation of the role of TNF-a converting enzyme (TACE) in the inhibition of cell surface and soluble TNF-a production by acute ethanol exposure. PLoS One 2012;7:e29890.
12. Wu D, Peng F, Zhang B. Collagen I induction by high glucose levels is mediated by epidermal growth factor receptor and phosphoinositide 3-kinase/Akt signalling in mesangial cells. Diabetologia 2007;50:2008-2018. (Pubitemid 47222845)
13. Ohta S, Harigai M, Tanaka M, et al. Tumor necrosis factor-a (TNF-a) converting enzyme contributes to production of TNF-a in synovial tissues from patients with rheumatoid arthritis. J Rheumatol 2001;28:1756-1763. (Pubitemid 32726920)
14. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 2008;4:300-309. (Pubitemid 351791441)
15. Bohgaki T, Amasaki Y, Nishimura N, et al. Up regulated expression of tumour necrosis factor a converting enzyme in peripheral monocytes of patients with early systemic sclerosis. Ann Rheum Dis 2005;64:1165-1173. (Pubitemid 41113351)
16. Leco KJ, Waterhouse P, Sanchez OH, et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001;108:817-829. (Pubitemid 32884192)
17. -/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet 2004;36:969-977. (Pubitemid 39167493)
18. Smookler DS, Mohammed FF, Kassiri Z, et al. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 2006;176:721-725. (Pubitemid 43099666)
19. Torring N, Sorensen BS, Bosch ST, et al. Amphiregulin is expressed in primary cultures of prostate myofibroblasts, fibroblasts, epithelial cells, and in prostate tissue. Prostate Cancer Prostatic Dis 1998;1:262-267. (Pubitemid 128545874)
20. Tokiyama K, Yokota E, Niho Y. Epidermal growth factor receptor of fibroblasts from patients with scleroderma. J Rheumatol 1990;17:1463-1468.
21. Wang P, Tian Q, Liang ZX, et al. Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin. Chin Med J (Engl) 2010;123:2259-2264.